CGS-20625

CGS-20625 is an anxiolytic drug used in scientific research. It has similar effects to benzodiazepine drugs,^[1] but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic.^[2][3] It produces anxiolytic and anticonvulsant effects, but with no sedative effects even at high doses, and no significant muscle relaxant effects.^[4] It is orally active in humans, but with relatively low bioavailability.^[5]

CGS-20625

Clinical data
Routes of administration	By mouth
ATC code	none
Pharmacokinetic data
Bioavailability	41%
Identifiers
IUPAC name 5,6,7,8,9,10-hexahydro-2-(4-methoxyphenyl)-cyclohepta[b]pyrazolo[3,4-d]pyridin-3(2H)-one
CAS Number	111205-55-1 Y
PubChem CID	163844
ChemSpider	143700 N
UNII	K9Q4R9S81O
CompTox Dashboard (EPA)	DTXSID30912046
Chemical and physical data
Formula	C18H19N3O2
Molar mass	309.369 g·mol−1
3D model (JSmol)	Interactive image
SMILES COC1=CC=C(C=C1)N2C(=O)C3=CN=C4CCCCCC4=C3N2
InChI InChI=1S/C18H19N3O2/c1-23-13-9-7-12(8-10-13)21-18(22)15-11-19-16-6-4-2-3-5-14(16)17(15)20-21/h7-11,20H,2-6H2,1H3 N Key:UBLXQFIFWUEVGJ-UHFFFAOYSA-N N
NY (what is this?)  (verify)

CGS-20625 is a positive allosteric modulator at several GABA_A receptors types. Due to its alicyclic moiety potency at γ1 subunit, containing receptor types is more pronounced for CGS-20625 compared to benzodiazepines.^[1] γ1 subunits are expressed at higher levels in the central amygdala.^[6]